Contract drug manufacturer Catalent Inc. agreed to buy closely held Paragon Bioservices Inc. for $1.2 billion, according to people familiar with the matter...
Fake shopping sprees and ‘happiness insurance’: The latest fintech apps reveal our financial anxieties






